BRIX1 and urinary bladder cancer: In addition, because BXDC2-negative/AR-positive tumors were strongly associated with resistance to CDDP-based chemotherapy, the expression status of BXDC2, along with that of AR, might serve as a predictor of chemosensitivity in patients with bladder cancer.